Group items tagged

Tynor R O M Knee Brace Prefabricated, custom adjusted R.O.M. Knee Brace controls and restrict flexion/extension of the knee joint through a multi-point joint fixation system to allow a range of motion or immobilization to the knee. Universal design allows it to be used on quite a big range of population and for a multiple orthopedic problems associated with knee joint. Immobilization at any angle Controlled motion between any two angles Quick and easy application and removal. Tynor R O M Knee Brace Features R.O.M. Dial 0 to 120 degree flexion. 0 to 60 degree hyper extention Locking at any angle or motion between any two angles possible Interval of 10 to15 degrees Pleasurable locking, using easy pull mechanism Neoprene Liner with Silicone Coating Enhanced product grip Less slippage of product High cushioning coefficient and more comfort Less discomfort of tight straps Ergonomic Design Light in weight Bilateral symmetrical Improved patient compliance Easy removal and application Universal design, one size fits all Straps with Reverse Buckle Mechanism Enhanced grip Easy to wear Controlled tightening.

PF Night Splint (Derotation) Applications Prevention and correction of foot drop. Night splint for early healing. Ambulatory, can be used as a day splint. Perfect post-operative immobilisation and derotation. Peroneal / Peritibial nerve or muscle damage. Ankle or Plantar flexion contracture and functional alignment. Can be used to protect the diabetic/ injured ankle & foot. PF Night Splint (Derotation) Features Removable de-rotation bar. Moulded foot casing, aesthetically pleasing and durable. Effective Liner, improved comfort. Highly functional Design, customized degree of dorsiflexion. Double strapping mechanism, better grip.

Uma alimentação saudável é essencial para que viva e se sinta bem, para tal é preciso conhecer o seu corpo e aprender a dar ao seu organismo o que ele realmente precisa. Quantas vezes pára para pensar nos seus hábitos alimentares? O stress e o ritmo acelerado do dia-a-dia, muitas vezes fazem-nos esquecer da importância de nos alimentarmos correctamente.

Ergo Wheelchair features an ergonomic "S" shaped seat that provides the perfect shape to fit the human body to relieve pressure, increase stabilization, weight distribution and lower the risk of pressure sores and scoliosis. Ergonomic wheelchair series provides users with a large selection of ultra lightweight wheelchairs that can help improve life. This series has features that include a high strength lightweight frame, foldable and easy to store, breathable anti-bacterial, anti-staining, removable and machine washable cushion. Also includes the exclusive S-Shape Seating System, which provides increased stability, better weight distribution and lowers the risk of pressure sores and spinal injury. Karma S Ergo 115 Wheelchair: This model features our S-Shape Seating System and is our number one best seller for many reasons. At a mere 11.3 kg in weight with detachable foot rest and many features such as removable machine washable and dry-able cushions treated by AEIGIS treated anti-microbial coated seating system. Karma S-Ergo 115 Wheelchair Features: Ergonomic Handrims & S-Shape Ergonomic Seating System Fixed armrest w/ wider concave armpads Swing In & Away Footrests Backrest Pouch attached to the upholstery 24" flat free polyurethane tires, high tread, flat free wheels Seat width: 16"x17" or 18"x17" or 20"x 17" Silver 1/4" Aegis Anti-Bacterial Upholstery, washable Folding backrest / folding seat for easy traveling "Tube-in Center" foot-plate, assures better side leg support High strength, starting weight at only 11.3 kg. (w/o footrests) 7×1" Polyurethane front casters Upholstery: Black breathable mesh bottom & top AEIGIS Frame Color: Pearl Silver or Rose Red Weight Capacity of 115 kg. Karma S-Ergo 115 Wheelchair Measurements: Seat Width 16 inch., 18 inch., 20 inch. Seat Depth 17 inch. Armrest Height 8 inch. Seat Height 19 inch. Back Height 17 inch. Overall Height 36 inch. Overall Open Width 23 inch., 25 inch., 27 inch

There is a realistic possibility of large waves of Covid-19 infection in the future in Britain and such waves might even be considered likely, epidemiologists who model the Covid-19 pandemic to inform government advice have said. Prime minister Boris Johnson has ditched legal restrictions in England, saying that, while the pandemic was not over, Britain needs to learn to live with Covid. The Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) said the emergence of new viral variants was the biggest unknown factor in the medium-to-long term, along with waning population immunity and changes in mixing patterns. "Large future waves of infection that need active management to prevent detrimental pressure on the health and care sector are, at least, a realistic possibility (high confidence) or likely (medium confidence)," SPI-M-O said in a consensus statement published on Friday.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

Superdrug, one of the leading health and beauty retailers, is all set to invest in 25 new stores this year, expanding its bricks-and-mortar retail footprint. It confirmed with Pharmacy Business that amongst its 25 new stores there "will be a mix of pharmacy and retail stores". The venture is expected to create over 570 jobs nationwide, creating a seamless customer experience and providing vital support for high streets and local communities. The investment, part of the brand's O+O (Online + Offline) platform strategy to deliver its omnichannel ambitions, is driven by continued strong performance figures. In Q4 2022 Superdrug reported increased volume and value sales and footfall across both sides of the beauty and health business. Whilst in 2021 revenue rose 5.1% to £1,168million with a profit before tax increase of 141.3%. The investment strategy has already seen Superdrug open new stores in Washington Gallery and Falkirk Retail Parks in February 2023 and in Braehead, the largest Superdrug in Scotland, just last month.

Nếu bạn đang băn khoăn về vấn đề chữa bệnh trĩ ở đâu trên Hà Nội uy tín thì hãy đến với phòng khám Thiên Tâm chúng tôi để nhận được sự phục vụ tốt nhất